# Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

*PRI Rank #4 · Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/rank-4*

| Field | Value |
| --- | --- |
| Rank | #4 |
| 18m citations | 116 |
| Journal | The Lancet |
| Year | 2024 |
| DOI | 10.1016/s0140-6736(24)00063-1 |
| Corresponding authors | Jeffrey S. Heier |
| Institution | University of Udine, Italy |

**Ranking page:** [Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026](https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026)

**Paper link:** [10.1016/s0140-6736(24)00063-1](https://doi.org/10.1016/s0140-6736(24)00063-1)

## Topics

Aflibercept · Neovascular age-related macular degeneration · PULSAR trial · Noninferiority trial design · Extended dosing interval · Anti-VEGF therapy · Best-corrected visual acuity (BCVA) · Aflibercept · Extended dosing interval · Intraretinal fluid resolution

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```